Please wait a minute...
Reviews in Cardiovascular Medicine  2015, Vol. 16 Issue (2): 125-130     DOI: 10.3909/ricm0762
Review Previous articles | Next articles
Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial
Boback Ziaeian1, 2, John Dinkler1, 2, Karol Watson1, 3
1 Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA
2 Jonathan and Karin Fielding School of Public Health at UCLA, Los Angeles, CA
3 UCLA Barbra Streisand Women's Heart Health Program, Los Angeles, CA
Download:  PDF(552KB)  ( 24 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in developed countries. The management of blood cholesterol through use of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) in at-risk patients is a pillar of medical therapy for the primary and secondary prevention of cardiovascular disease. The recent 2013 American College of Cardiology/American Heart Association guideline on managing blood cholesterol provides an important framework for the effective implementation of risk-reduction strategies. The guideline identifies four cohorts of patients with proven benefits from statin therapy and streamlines the dosing and monitoring recommendations based on evidence from published, randomized controlled trials. Primary care physicians and cardiologists play key roles in identifying populations at elevated ASCVD risk. In providing a practical management overview of the current blood cholesterol guideline, we facilitate more informed discussions on treatment options between healthcare providers and their patients.
Key words:  Atherosclerotic cardiovascular disease      Low-density lipoprotein cholesterol      High-density lipoprotein cholesterol      Risk reduction      Statin drugs      IMPROVE-IT     
Published:  30 June 2015     

Cite this article: 

Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0762     OR     https://rcm.imrpress.com/EN/Y2015/V16/I2/125

[1] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[2] Seth J. Baum, Daniel Soffe, P. Barton Duell. Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 16-27.
[3] Norman E. Lepor, Laurn Contreras, Chirag Desai, Dean J. Kereiakes. The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 290-309.
[4] Karol E. Watson, Eric H. Stocker, Douglas S. Jacoby, Peter A. McCullough. Advanced Lipid Testing: When, Why, and In Whom?[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 310-319.
[5] Divya Ratan Verma, Eliot A. Brinton. Management of Hypercholesterolemia for Prevention of Atherosclerotic Cardiovascular Disease: Focus on the Potential Role of Recombinant Anti-PCSK9 Monoclonal Antibodies[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 86-101.
[6] Emil M. deGoma. Lomitapide for the Management of Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 109-118.
[7] Peter P. Toth, Prediman K. Shah, Michael J. Wilkinson, Michael H. Davidson, Peter A. McCullough. Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice[J]. Reviews in Cardiovascular Medicine, 2014, 15(1): 1-10.
[8] Prediman K. Shah. Residual Risk and High-Density Lipoprotein Cholesterol Levels: Is There a Relationship?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 55-59.
[9] Gustavo A. Cardenas, Carl J. Lavie, Vanessa Cardenas, Richard V. Milani, Peter A. McCullough. The Importance of Recognizing and Treating Low Levels of High-Density Lipoprotein Cholesterol: A New Era in Atherosclerosis Management[J]. Reviews in Cardiovascular Medicine, 2008, 9(4): 239-258.
[10] Vasilios Papademetriou. Cardiovascular Protection Paradigms: Is Change on the Horizon?[J]. Reviews in Cardiovascular Medicine, 2007, 8(4): 200-213.
[11] Stuart W. Zarich. Cardiovascular Risk Factors in the Metabolic Syndrome: Impact of Insulin Resistance on Lipids, Hypertension, and the Development of Diabetes and Cardiac Events[J]. Reviews in Cardiovascular Medicine, 2005, 6(4): 194-205.
[12] Robert A.Vogel. Alcohol, Heart Disease, and Mortality: A Review[J]. Reviews in Cardiovascular Medicine, 2002, 3(1): 7-13.
No Suggested Reading articles found!